lev-os Informed Consent Form
Drafts a defensible informed consent form satisfying disclosure obligations and documenting voluntary, knowing authorization.
Quick Start
Gather before drafting:
- Jurisdiction — which consent standard applies (professional, reasonable person, or subjective)
- Regulatory framework — HIPAA, FDA, IRB/Common Rule, ICH-GCP, state rules
- Procedure details — protocol, personnel, timeline, devices, medications
- Participant population — capacity issues, language needs, literacy level
- Institutional requirements — templates, mandatory language, formatting
Core Sections
1. Procedure Description
| Element | Include |
|---|---|
| Process overview | Prep, intervention, follow-up in plain language; define terms parenthetically |
| Timeline | Frequency, duration, total commitment |
| Personnel | Qualifications of those performing/supervising |
| Materials | Equipment, medications, devices with lay explanations |
| Participant burden | Physical demands, time, lifestyle changes, emotional impact |
2. Risk Disclosure and Benefits
Risk frequency tiers — use consistently:
| Tier | Frequency | Label |
|---|---|---|
| Common | >10% | "commonly" / "frequently" |
| Occasional | 1–10% | "occasionally" / "sometimes" |
| Rare | <1% | "rarely" |
| Isolated | Case reports only | "in isolated cases" |
For each material risk: nature of harm, severity, temporary vs. permanent, mitigation.
Benefits: realistic expectations only, no guarantees. State if experimental. Include statistical context when available.
3. Alternatives and Right to Refuse
- Each viable alternative with comparative risk/benefit/cost analysis
- Less invasive options and conservative management
- Option to decline — natural course explained factually
- No-coercion language: refusal won't cause abandonment or care loss
- If no alternatives exist, state clinical basis
4. Privacy and Information Governance
- Data collected, purpose, retention, access (care team, researchers, regulators)
- Applicable privacy framework (HIPAA, FERPA, state statutes)
- Confidentiality limits: mandatory reporting, court orders, safety exceptions
- Secondary uses require separate consent (QI, teaching, research, publication)
- Safeguards described; participant rights to access/correct data
- Certificate of Confidentiality status (research)
5. Participant Rights and Withdrawal
- Unconditional right to withdraw without penalty
- Withdrawal process: contact, written notice, data/specimen disposition
- Honest disclosure of practical limitations (irreversible steps, published aggregates)
- Right to ask questions at any point
- Contact info for questions, adverse events, complaints
- Financial transparency: covered costs, out-of-pocket, compensation
6. Signature and Execution Block
Include all that apply:
Primary participant — attestations: read/understood, opportunity to ask questions, voluntary consent. Signature, printed name, date.
Authorized representative (if participant lacks capacity) — signature, printed name, date, relationship, legal basis for authority.
Person obtaining consent — attestation that procedure was explained and participant demonstrated understanding. Signature, printed name/title, date.
Witness (when required by regulation/policy) — attestation of observing consent process. Signature, printed name, date.
Separate opt-in/opt-out blocks for each ancillary authorization:
- Photography/video
- Specimen use for future research
- Contact for additional studies
- Third-party information release
Document control footer: version number, effective date, supersedes date, page X of Y.
Include statement: participant receives a complete signed copy.
Drafting Rules
- Jurisdiction-first — confirm applicable consent standard before drafting; requirements vary by state
- Plain language — active voice, short sentences, common words; define technical terms parenthetically; 12pt minimum font
- Material risk standard — disclose any risk a reasonable person would consider significant; err toward over-disclosure
- No guarantees — use "may," "expected," "typical"; never promise outcomes
- Selective consent — participants must decline ancillary authorizations without affecting primary consent
- Capacity accommodations — address literacy, language, cognitive limitations in the attestation
Pitfalls
- Skipping jurisdictional analysis — consent standards differ significantly by state; a form valid in one may be inadequate in another
- Burying risks — material risks must be prominent, not hidden in dense paragraphs
- Coercive framing — refusal language must be neutral; never imply negative consequences for declining
- Missing withdrawal limits — state honestly which steps are irreversible; omission undermines defensibility
Final Check
- Applicable regulatory frameworks identified and addressed
- All material risks disclosed with frequency tier labels
- Alternatives section includes option to decline
- Privacy section covers confidentiality limitations
- Signature blocks match participant population (capacity, witnesses)
- Ancillary authorizations are separate opt-in/opt-out
- Document control footer with version, date, pagination
- Flag for review by legal counsel, compliance, and IRB/ethics committee (if research)